Ocular Therapeutix (NASDAQ:OCUL) Announces Earnings Results, Misses Expectations By $0.08 EPS

Key Points

• Missed expectations: Ocular Therapeutix reported Q1 EPS of ($0.40) versus consensus ($0.32) and revenue of $10.79M versus $12.72M, alongside very weak profitability metrics (net margin -511.9%, negative ROE).
• AXPAXLI Phase 3 success: SOL‑1 showed statistical superiority to aflibercept (P=0.0006) with about two‑thirds of patients maintaining vision after a single injection for a year and no treatment‑related serious ocular/systemic adverse events; the company plans to pursue an NDA based on week‑52 SOL‑1 data while SOL‑R enrollment exceeded targets and topline is guided to Q1 2027.
• $666.7M cash runway: The company ended Q1 with roughly $666.7M in cash, supporting operations into 2028 and upcoming catalysts (Investor Day June 17, SOL‑R topline Q1 2027) while analysts hold a consensus "Moderate Buy" with an average target of $23.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08), FiscalAI reports. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $12.72 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The company's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.38) EPS.

Here are the key takeaways from Ocular Therapeutix's conference call:

• AXPAXLI demonstrated statistical superiority to aflibercept in SOL-1 (primary endpoint P=0.0006) with unmatched durability—about two-thirds of patients maintained vision after a single injection for a year.
• The company reported a reassuring safety profile for AXPAXLI in SOL-1, with no treatment-related serious ocular or systemic adverse events (e.g., endophthalmitis or vasculitis) observed in presented subject-level data.
• SOL-R exceeded enrollment expectations (631 randomized vs. 555 target) with top-line now guided to Q1 2027, and SOL-X (a 3-year open-label extension) has begun enrollment to evaluate long-term outcomes and crossover effects.
• Ocular plans to submit an NDA relying on SOL-1 week‑52 data and to use the 505(b)(2) pathway, but formal discussions with the FDA are ongoing and could affect timing or data requirements.
• The company ended Q1 with approximately $667 million in cash, providing runway into 2028 to support trials, NDA activities, and commercial readiness, although this figure does not include the full anticipated commercialization expenses.

Ocular Therapeutix Trading Down 0.6%

Shares of NASDAQ:OCUL opened at $9.71 on Wednesday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -6.74 and a beta of 0.93. Ocular Therapeutix has a 12 month low of $6.23 and a 12 month high of $16.44. The company's fifty day simple moving average is $9.04 and its 200 day simple moving average is $10.54. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11.

Wall Street Analysts Forecast Growth

OCUL has been the subject of several research reports. Royal Bank Of Canada restated an "outperform" rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a research report on Tuesday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Monday, April 13th. Jefferies Financial Group reissued a "buy" rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $23.78.

Ocular Therapeutix News Summary

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Announced positive Phase 3 SOL‑1 Week 52 results and accelerated commercial preparedness with plans to seek FDA review of AXPAXLI (based on SOL‑1 Week 52 data), which materially improves the company's path to commercialization if accepted. Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: SOL‑R Phase 3 (non‑inferiority) remains on track for a topline readout in Q1 2027 and enrollment is progressing for the SOL‑X long‑term extension, preserving multiple upcoming clinical milestones that could be future catalysts. Ocular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA plan
• Positive Sentiment: Strong cash position — $666.7M at 3/31/26 — gives the company runway into 2028, reducing near‑term financing risk while it advances regulatory and commercial plans. Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
• Neutral Sentiment: Company set an Investor Day for June 17, 2026 (NYC) — a potential informational catalyst where management may provide finer NDA timing and commercialization detail. Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
• Negative Sentiment: Q1 results missed expectations: GAAP loss per share larger than consensus (roughly -$0.40 vs. est. -$0.32) and revenue of $10.79M missed estimates (~$12.7M), driving short‑term investor concern about near‑term financial performance. Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Profitability metrics remain weak (large negative net margin and negative ROE) and analysts expect continued losses this year, keeping the stock sensitive to execution and regulatory timing. Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Insider Transactions at Ocular Therapeutix

In other news, Director Richard L. Md Lindstrom purchased 60,229 shares of the business's stock in a transaction dated Friday, February 20th. The shares were bought at an average cost of $7.66 per share, for a total transaction of $461,354.14. Following the completion of the acquisition, the director directly owned 246,933 shares in the company, valued at approximately $1,891,506.78. This trade represents a 32.26% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Nadia Waheed sold 7,863 shares of the company's stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $71,081.52. Following the transaction, the insider directly owned 318,417 shares of the company's stock, valued at $2,878,489.68. This represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 185,731 shares of company stock worth $1,653,407. Company insiders own 2.30% of the company's stock.

Institutional Investors Weigh In On Ocular Therapeutix

Hedge funds and other institutional investors have recently bought and sold shares of the company. TCG Crossover Management LLC boosted its position in Ocular Therapeutix by 15.0% during the 3rd quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company's stock worth $71,510,000 after acquiring an additional 798,084 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Ocular Therapeutix by 15.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company's stock worth $56,148,000 after acquiring an additional 620,700 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Ocular Therapeutix by 30.5% in the fourth quarter. Geode Capital Management LLC now owns 4,356,547 shares of the biopharmaceutical company's stock valued at $52,896,000 after purchasing an additional 1,018,094 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Ocular Therapeutix by 106.5% in the fourth quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company's stock valued at $51,321,000 after purchasing an additional 2,180,702 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Ocular Therapeutix by 21.3% in the fourth quarter. State Street Corp now owns 4,196,330 shares of the biopharmaceutical company's stock worth $50,943,000 after purchasing an additional 736,318 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.